The Claim
In a randomized controlled trial of 14,752 adults with type 2 diabetes followed for a median of 3.2 years, once-weekly exenatide did not significantly reduce the risk of first hospitalization for heart failure, with a hazard ratio of 0.95 (95% CI 0.79–1.14), indicating a neutral effect on incident heart failure events despite observed benefits on recurrent events.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A weekly diabetes shot called exenatide doesn’t lower the chance of ending up in the hospital for heart failure for the first time in people with type 2 diabetes — it’s basically neutral, even though it might help if someone already has heart issues.
See the scientific wording
Once-weekly exenatide does not reduce the risk of first hospitalization for heart failure in adults with type 2 diabetes, with a hazard ratio of 0.95 (95% CI 0.79–1.14), based on a randomized controlled trial of 14,752 participants followed for a median of 3.2 years. This indicates neutrality on incident heart failure events, despite benefits on recurrent events.
What the research says
1 studyThe study looked at a diabetes drug given once a week and found it didn’t lower the chance of first hospitalization for heart failure, but did help reduce repeat hospitalizations. This matches what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.